A member of our group has received an award!
Riikka Viitanen, a PhD student at Turku PET Centre and Drug Research Doctoral Programme of University of Turku Graduate School, has been awarded the annual Alavi-Mandell Award from the Society of Nuclear Medicine and Molecular Imaging for her publication in the Journal of Nuclear Medicine. She is the first author of paper entitled with “68Ga-DOTA-E[c(RGDfK)]2 Positron Emission Tomography Imaging of SHARPIN-Regulated Integrin Activity in Mice”.
Alavi-Mandell Award is given to individuals who were the first author of a paper published in the Journal of Nuclear Medicine that were trainees at the time the published work was carried out and made a major contribution to the completion of the work. The Alavi-Mandell Award aims to encourage the young scientists to pursue a career in academic and research in nuclear medicine.
Meeri will defend her thesis titled “Gallium-68 radiolabeling of biomolecules for positron emission tomography with special reference to imaging of inflammation and bone”.
The public event will be held Saturday February 29th 2020 at 12 o’clock in the Lauren 2 lecture hall (Medisiina D, Kiinamyllynkatu 10). Associate Professor (VU University Amsterdam) will act as the opponent and professor Anne Roivainen as the custodian. The dissertation is in English.
The first VAP-1 targeted PET tracer [68Ga]Ga-DOTA-Siglec-9 has finally entered in clinical trials. Sofar, two healthy volunteers have successfully been imaged at Turku PET Centre. (ClinicalTrials.gov Identifier: NCT03755245: Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis (SIGLEC))
Max will publicly defend his PhD thesis “Molecular Imaging of Tissue Repair after Myocardial Infarction, Preclinical evaluation of novel (68)Ga-labeled PET tracers”.
The public event will be held Friday June 1st 2018 at 12 o’clock in the Risto Lahesmaa lecture hall (TYKS, T -hospital, Hämeentie 11). Professor John Prior (University of Lausanne) will act as the opponent and associate professor Antti Saraste (University of Turku) as the custodian. The dissertation is in English.
Roivainen group is a part of the Health from Science programme (TERVA) of the Academy of Finland. The programme spans from 2018 to 2020.
Our project in the programme is Reprogramming of macrophage phenotypes as early predictor of cardiovascular and metabolic disease development (MAP-CAD). One of our postdocs, Senthil Palani, is already working hard on the project.
Funding decicions for the TERVA programme were made november 2017.
Link to TERVA programme Homepage.